Unlike the other cancer types discussed above, targeted therapy has also shown disappointing results in BRAF-mutant CRC with monotherapies being mainly inefficacious and combination therapies, including immunotherapy-based regimens, achieving ORR in just about 30% of patients [95]. The gene discussed is BRAF; the disease is cancer.